← Search

Omics · study · 2026

RNA profiling of wild-type Osteosarcoma (U2OS) cells and its KO derivative (PERK KO) upon Palbociclib treatment for 4 days

Listed in NCBI GEO

Dysregulation of cyclin-dependent kinase 4/6 (CDK4/6) occurs in various cancers.

Description

Three CDK4/6 inhibitors are approved for clinical use including Palbociclib (PD). CDK4/6 inhibitors trigger early G1 cell cycle arrest in cells, leading to cellular quiescence while long term inhibition enforces transition to senescence.

PERK is a shared Kinase between the Unfolded Protein Response (UPR) and the Integrated Stress Response (ISR). We report that PERK inhibition accelerate Palbociclib induce senescence.

Links

Where it is published

Documentation and papers

Topics

From keywords
Life Sciences
Provenance · 1 source records, 7 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE29463515 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title